<DOC>
	<DOCNO>NCT00642473</DOCNO>
	<brief_summary>This study evaluate efficacy safety metronidazole actavis 1 percent ( % ) topical cream prevention treatment rash associate Tarceva treatment , participant non-small cell lung cancer . The first cohort participant enrol study treat twice daily metronidazole cream right side face upper thorax , day start treatment Tarceva ( 150 mg orally daily ) . The correspond body part leave side treat accord local standard procedure ( ie , non-active moisturizing cream ) . The second cohort Tarceva-treated participant receive twice daily treatment metronidazole cream develop rash . In cohort , efficacy evaluate Week 2 Week 4 . The anticipated time metronidazole treatment le ( &lt; ) 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Metronidazole Cream Prevention Treatment Tarceva ( Erlotinib ) -Associated Rash</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>nonsmall cell lung cancer eligible start treatment erlotinib hypersensitivity metronidazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>